Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for AMR Prevention in Sensitized Deceased Donor Kidney Transplant Recipients
NCT01567085Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2012
- Primary completion
- Jun 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of eculizumab in antibody mediated rejection (AMR), sponsored by Alexion Pharmaceuticals. Started Aug 2012; status: completed.
02
Drugs
eculizumab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT01567085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01567085.